Anika Therapeutics (NASDAQ:ANIK) and Lyell Immunopharma (NASDAQ:LYEL) Critical Contrast

Anika Therapeutics (NASDAQ:ANIK) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, institutional ownership, earnings, valuation and profitability.

Profitability

This table compares Anika Therapeutics and Lyell Immunopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Anika Therapeutics	-3.14%	0.20%	0.15%
Lyell Immunopharma	-920,285.25%	-91.62%	-70.50%

Volatility and Risk

Anika Therapeutics has a beta of 0.2, meaning that its stock price is 80% less volatile than the S&P 500. Comparatively, Lyell Immunopharma has a beta of -0.04, meaning that its stock price is 104% less volatile than the S&P 500.

Institutional and Insider Ownership

91.5% of Anika Therapeutics shares are held by institutional investors. Comparatively, 66.0% of Lyell Immunopharma shares are held by institutional investors. 12.1% of Anika Therapeutics shares are held by insiders. Comparatively, 6.2% of Lyell Immunopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for Anika Therapeutics and Lyell Immunopharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anika Therapeutics	1	0	2	1	2.75
Lyell Immunopharma	1	1	6	1	2.78

Anika Therapeutics currently has a consensus target price of $21.00, suggesting a potential downside of 0.21%. Lyell Immunopharma has a consensus target price of $40.86, suggesting a potential upside of 279.54%. Given Lyell Immunopharma’s stronger consensus rating and higher probable upside, analysts plainly believe Lyell Immunopharma is more favorable than Anika Therapeutics.

Earnings and Valuation

This table compares Anika Therapeutics and Lyell Immunopharma”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anika Therapeutics	$112.82 million	2.50	-$10.88 million	($0.27)	-77.94
Lyell Immunopharma	$40,000.00	6,593.56	-$274.45 million	($12.83)	-0.84

Anika Therapeutics has higher revenue and earnings than Lyell Immunopharma. Anika Therapeutics is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Summary

Anika Therapeutics beats Lyell Immunopharma on 9 of the 14 factors compared between the two stocks.

About Anika Therapeutics

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company’s joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

About Lyell Immunopharma

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.